American Society of Hematology

Figure 4.

$Figure 4. Internucleosomal DNA fragmentation and decrease in DNA content are not observed in zVAD + imatinib–induced atypical cell death. BV173 cells were treated with DMSO, imatinib, and zVAD + imatinib for 3, 6, and 12 hours, followed by internucleosomal DNA fragmentation assay and DNA content assay (“Materials and methods”). Internucleosomal DNA fragmentation (A) and decrease in DNA content (B) were observed and augmented in a time-dependent fashion in imatinib-treated cells, whereas neither was observed in zVAD + imatinib–treated cells. M indicates 100–base pair ladder molecular-weight standard; C, control. Values in B indicate the percentage of sub-G1 fraction. Results are representative of 3 individual experiments.$

Internucleosomal DNA fragmentation and decrease in DNA content are not observed in zVAD + imatinib–induced atypical cell death. BV173 cells were treated with DMSO, imatinib, and zVAD + imatinib for 3, 6, and 12 hours, followed by internucleosomal DNA fragmentation assay and DNA content assay (“Materials and methods”). Internucleosomal DNA fragmentation (A) and decrease in DNA content (B) were observed and augmented in a time-dependent fashion in imatinib-treated cells, whereas neither was observed in zVAD + imatinib–treated cells. M indicates 100–base pair ladder molecular-weight standard; C, control. Values in B indicate the percentage of sub-G₁ fraction. Results are representative of 3 individual experiments.

This Feature Is Available To Subscribers Only